ArticleCancer2026
Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSexual orientation and gender identity (SOGI) minorities experience disparities in health care access and quality of care, however national evidence regarding adherence to recommended cancer screening remains limited. This study aimed to evaluate associations between SOGI status and adherence to US Preventive Services Task Force-recommended colorectal, cervical, and breast cancer screening.
methodsAdults eligible for colorectal (CRC; 45-74 years old), cervical (25-64 years old), or breast cancer (40-74 years old) screening were identified from the 2018-2022 Behavioral Risk Factor Surveillance System according to guideline-concordant criteria. Respondents were categorized as sexual orientation minorities (SOM) versus heterosexual and as gender identity minorities (GIM) versus cisgender. Univariable results were reported as unweighted frequencies with survey-weighted proportions. Survey-weighted Poisson regression models were used to estimate adjusted prevalence ratios (aPRs) for screening adherence.
resultsAmong 663,924 unweighted screening-eligible respondents, weighted 1.2% (n = 8108) identified as SOM and 0.4% (n = 2315) as GIM; 33.5% (n = 223,065) were assigned male at birth and 67.9% (n = 522,845) identified as White. After adjustment for covariates, SOM was associated with lower adherence to cervical (aPR, 0.92; 95% CI, 0.87-0.97) and breast cancer screening (aPR, 0.84; 95% CI, 0.77-0.92) compared with heterosexual women. CRC screening adherence among SOM men was slightly higher (aPR, 1.10; 95% CI, 1.00-1.21). GIM status was associated with substantially lower adherence to cervical (aPR, 0.58; 95% CI, 0.37-0.90) and breast cancer screening (aPR, 0.24; 95% CI, 0.08-0.74) compared with cisgender respondents, with no difference in CRC screening (p > .05).
conclusionsDisparities in cervical and breast cancer screening persist among SOGI minorities. These findings underscore prevalent structural and systemic barriers in preventive cancer care and highlight the need for inclusive, culturally sensitive interventions to promote equitable screening access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.